Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
Portfolio Pulse from
Ascletis Pharma has completed enrollment for a Phase III trial of ASC40, a once-daily oral tablet for treating moderate to severe acne. The trial includes 480 patients, with results expected in Q2 2025.
November 12, 2024 | 11:45 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Ascletis Pharma has completed patient enrollment for its Phase III trial of ASC40, targeting moderate to severe acne. Results are anticipated in Q2 2025, which could impact the company's market position in acne treatment.
The completion of enrollment for a Phase III trial is a significant milestone for Ascletis Pharma, indicating progress in their product development pipeline. However, the impact on stock price is neutral in the short term as results are not expected until Q2 2025.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80